Medivir to develop new drugs for bacterial infections
Swedish University of Agricultural Sciences will receive a fee for research services
Medivir, a Swedish research-based pharmaceutical company focused on infectious diseases, is to collaborate with scientists at the Swedish University of Agricultural Sciences (SLU) to develop new drugs against antibiotic-resistant bacteria.
The researchers at the SLU have developed low molecular-weight chemical compounds with potentially novel mechanisms of action that may serve as the starting point for developing new antibiotics to treat severe bacterial infections.
Medivir will further develop the substances that the SLU researchers identify in this early screening collaboration.
The firm will pay the SLU an unspecified fee for research services during the screening process and a minor part of future revenues associated with any further development or commercialisation.
